Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2020

Nov 09, 2020

SELL
$10.6 - $16.6 $420,014 - $657,758
-39,624 Closed
0 $0
Q1 2020

May 07, 2020

SELL
$11.0 - $31.7 $44,000 - $126,800
-4,000 Reduced 9.17%
39,624 $51,000
Q4 2019

Feb 13, 2020

BUY
$10.6 - $24.1 $462,414 - $1.05 Million
43,624 New
43,624 $98,000

About Cellectar Biosciences, Inc.


  • Ticker CLRB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 6,114,290
  • Market Cap $13M
  • Description
  • Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study in patients with relapsed or refractory (r/r) Waldenstrom's ma...
More about CLRB
Track This Portfolio

Track Game Plan Financial Advisors, LLC Portfolio

Follow Game Plan Financial Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Game Plan Financial Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Game Plan Financial Advisors, LLC with notifications on news.